Abstract
Xanthine oxidoreductase (XOR), a complex flavoprotein, catalyzes the metabolic reactions leading from hypoxanthine to xanthine and from xanthine to urate, and both reactions take place at the molybdenum cofactor. The enzyme is a target of drugs for therapy of gout or hyperuricemia. We review the chemical nature and reaction mechanisms of the molybdenum cofactor of XOR, focusing on molybdenum-dependent reactions of actual or potential medical importance, including nitric oxide (NO) synthesis. It is now generally accepted that XOR transfers the water-exchangeable -OH ligand of the molybdenum atom to the substrate. The hydroxyl group at OHMo( IV) can be replaced by urate, oxipurinol and FYX-051 derivatives and the structures of these complexes have been determined by xray crystallography under anaerobic conditions. Although formation of NO from nitrite or formation of xanthine from urate by XOR is chemically feasible, it is not yet clear whether these reactions have any physiological significance since the reactions are catalyzed at a slow rate even under anaerobic conditions.
Keywords: Xanthine oxidase, xanthine dehydrogenase, complex flavoprotein, molybdenum cofactor, uric acid, nitic oxide
Current Pharmaceutical Design
Title:Chemical Nature and Reaction Mechanisms of the Molybdenum Cofactor of Xanthine Oxidoreductase
Volume: 19 Issue: 14
Author(s): Ken Okamoto, Teruo Kusano and Takeshi Nishino
Affiliation:
Keywords: Xanthine oxidase, xanthine dehydrogenase, complex flavoprotein, molybdenum cofactor, uric acid, nitic oxide
Abstract: Xanthine oxidoreductase (XOR), a complex flavoprotein, catalyzes the metabolic reactions leading from hypoxanthine to xanthine and from xanthine to urate, and both reactions take place at the molybdenum cofactor. The enzyme is a target of drugs for therapy of gout or hyperuricemia. We review the chemical nature and reaction mechanisms of the molybdenum cofactor of XOR, focusing on molybdenum-dependent reactions of actual or potential medical importance, including nitric oxide (NO) synthesis. It is now generally accepted that XOR transfers the water-exchangeable -OH ligand of the molybdenum atom to the substrate. The hydroxyl group at OHMo( IV) can be replaced by urate, oxipurinol and FYX-051 derivatives and the structures of these complexes have been determined by xray crystallography under anaerobic conditions. Although formation of NO from nitrite or formation of xanthine from urate by XOR is chemically feasible, it is not yet clear whether these reactions have any physiological significance since the reactions are catalyzed at a slow rate even under anaerobic conditions.
Export Options
About this article
Cite this article as:
Okamoto Ken, Kusano Teruo and Nishino Takeshi, Chemical Nature and Reaction Mechanisms of the Molybdenum Cofactor of Xanthine Oxidoreductase, Current Pharmaceutical Design 2013; 19 (14) . https://dx.doi.org/10.2174/1381612811319140010
DOI https://dx.doi.org/10.2174/1381612811319140010 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sirtuins: Possible Clinical Implications in Cardio and Cerebrovascular Diseases
Current Drug Targets Measurement of Physical Changes in the Myocardium for Development of Novel Methods for Diagnosing Ischemia
Current Cardiology Reviews Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Fatty Liver and Ischemia/Reperfusion: Are there Drugs Able to Mitigate Injury?
Current Medicinal Chemistry Cardiac Biomarkers in Acute Coronary Syndromes: A Review
Current Vascular Pharmacology Chagas Heart Disease Pathogenesis: One Mechanism or Many?
Current Molecular Medicine Circulatory Syndrome: An Evolution of the Metabolic Syndrome Concept!
Current Cardiology Reviews Heart Failure Modulates the Muscle Reflex
Current Cardiology Reviews Treatment of Chronic Peripheral Arterial Disease
Current Vascular Pharmacology Shut-Down of Translation, a Global Neuronal Stress Response:Mechanisms and Pathological Relevance
Current Pharmaceutical Design Women’s Ginseng (Angelica sinensis): An Ethnopharmacological Dossier
Current Traditional Medicine Ivabradine: Cardiovascular Effects
Recent Patents on Cardiovascular Drug Discovery The Role of T and B Cells in Atherosclerosis: Potential Clinical Implications
Current Pharmaceutical Design The Therapeutic Applications of Exosomes in Different Types of Diseases: A Review
Current Molecular Medicine Calcium Related Genes in Dogs as Potential Cardiac Biomarkers for the Detection of Chronic Mitral Valve Disease
Recent Patents on Biomarkers Carbon Monoxide in Renal Physiology, Pathogenesis and Treatment of Renal Disease
Current Pharmaceutical Design Innovative Strategies in In Vivo Apoptosis Imaging
Current Medicinal Chemistry The Influence of Obese Insulin-Resistance on the Outcome of the Ischemia/Reperfusion Insult to the Heart
Current Medicinal Chemistry Obesity and Cardioprotection
Current Medicinal Chemistry Pharmaceutical Measures to Prevent Doxorubicin-Induced Cardiotoxicity
Mini-Reviews in Medicinal Chemistry